ClinicalTrials.gg
RecruitingNCT04045691BERINGUpdated Jan 19, 2021

Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment

An observational study in Melanoma Stage IV and Melanoma Stage III, sponsored by Pierre Fabre Pharma GmbH. Recruiting at 59 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-19.

Sponsored by Pierre Fabre Pharma GmbH (part of Pierre Fabre) · Observational

From the registry’s dates

  • Started Oct 2019; still recruiting 7 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
750
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 284 studies in Melanoma with a site in Germany — 37 open to participants now, 70 under way, 20 of them phase 3. Melanoma · Germany.

Planned enrollment
12th of 32
750 · median 420
Started
2019
with 10 others
Observational
32 of 284
10 open now
Primary completion
2026-12
later than 24 of 69 live
Registered
201st of 284
by date

Among the 284 studies in Melanoma with a site in Germany, this one is the 12th largest by planned enrollment of the 32 observational ones that give a count, is one of 11 that started in 2019, is one of 32 observational ones, reaches primary completion later than 24 of the 69 other live ones, and was the 201st registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

37 of the 284 studies in Melanoma with a site in Germany are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Melanoma with a site in Germany, or all of them as a file.
02

Study summary

BERING-MELANOMA - designed as a prospective, longitudinal, non-interventional study - investigates real-world effectiveness, quality of life, safety and tolerability of encorafenib plus binimetinib in unresectable advanced or metastatic BRAF(Rapidly Accelerated Fibrosarcoma isoform B)-V600-mutant malignant melanoma after commercial availability of these two products in Germany, Austria and Switzerland. The study focusses on the documentation of the first and second line setting (i.e. after one line of prior checkpoint inhibition) by documenting patients treated according to the SmPC (Summary of Product Characteristics).

03

Conditions studied

  • Melanoma Stage IV
  • Melanoma Stage III

Browse trials for

Keywords

  • BERING
  • Encorafenib
  • Binimetinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with unresectable advanced or metastatic BRAFV600-mutant malignant melanoma, with a decision to receive targeted treatment with Encorafenib/Binimetinib according to the current SmPC.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written of the patient with regard to the pseudonymized documentation as well as the transfer and processing of his/her data within the study and the ADOREG [Cancer Registry of German Working Group of Dermato-Oncology] registry (data transfer to ADOREG registry only for patients from German sites);
  • Legally capable male or female patient ≥ 18 years of age (no upper limit);
  • Decision was taken to treat the patient with encorafenib plus binimetinib in accordance with the current SmPC [Summary of Product Characteristics] and by prescription; this decision was taken prior to and independent from the inclusion into the study;
  • Treatment with encorafenib plus binimetinib has been started ≤ 6 months prior to providing written informed consent for this study or is planned to be started in the near future;
  • Unresectable advanced or malignant melanoma with BRAF [Rapidly Accelerated Fibrosarcoma isoform B] V600 mutation;
  • Treatment-naive or after one prior line of treatment (anti-CTLA4 [Cytotoxic T-Lymphocyte Antigen-4] and/or anti-PD(L)1 [Programmed cell Death protein 1]) in the unresectable advanced or metastatic setting.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with a BRAF- and/or MEK [Mitogen-Activated Protein/Extracellular-signal Regulated Kinase]- inhibitor except for:

    -- prior treatment with BRAF+MEK-inhibitor combination therapy that ended > 6 months prior start of Encorafenib/Binimetinib treatment;

  • More than one prior line of treatment in the unresectable advanced or setting;
  • Any previous chemotherapeutic treatment of the melanoma disease;
  • Presence of any with regard to the encorafenib-binimetinib-treatment as specified in the corresponding SmPCs;
  • Current or upcoming participation in an interventional clinical trial;
  • Current or upcoming systemic treatment of any other tumor than melanoma;
  • Prisoners or persons who are compulsorily detained (involuntarily incarcerated).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
750 participants (estimated)
Patient registry
No

Interventions

  • Observation of real-life treatment with encorafenib and binimetinib

  • Observation of real-life treatment with encorafenib and binimetinib

06

What researchers measure

Primary outcomes

  1. Progression-free survival

    Progression-free survival rate

    Time frame: At 12 months after start of treatment

Secondary outcomes

  1. Patient and disease profiles at start of treatment with encorafenib plus binimetinib

    Demographic and disease characteristics

    Time frame: Baseline

  2. Type of treatments before and after encorafenib plus binimetinib

    Treatment sequence prior to and after encorafenib plus binimetinib; by documenting pre-treatments with adjuvant therapy and systemic therapy in palliative setting; and by documenting subsequent systemic treatment lines after administration of encorafenib plus binimetinib

    Time frame: Complete observation time-frame (the total observation period of this study will amount to 90 months).

  3. Sequence of treatments before and after encorafenib plus binimetinib

    Treatment sequence prior to and after encorafenib plus binimetinib; by documenting pre-treatments with adjuvant therapy and systemic therapy in palliative setting; and by documenting subsequent systemic treatment lines after administration of encorafenib plus binimetinib

    Time frame: Complete observation time-frame (the total observation period of this study will amount to 90 months).

  4. Characteristics of treatment with encorafenib plus binimetinib

    Evaluation of reason for treatment selection (efficacy, safety profile, quality of life, patients preference, physician's preference, comorbidities, other)

    Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)

  5. Effectiveness of treatment with encorafenib plus binimetinib

    Further progression-free survival parameters

    Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)

  6. Effectiveness of treatment with encorafenib plus binimetinib

    Time-to-progression

    Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)

  7. Effectiveness of treatment with encorafenib plus binimetinib

    Best observed tumor response

    Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)

  8. Effectiveness of treatment with encorafenib plus binimetinib

    Overall response rate

    Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)

  9. Effectiveness of treatment with encorafenib plus binimetinib

    Duration of response

    Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)

  10. Effectiveness of treatment with encorafenib plus binimetinib

    Disease control rate

    Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)

  11. Effectiveness of treatment with encorafenib plus binimetinib

    Duration of disease control

    Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)

  12. Effectiveness of treatment with encorafenib plus binimetinib

    Overall survival

    Time frame: Complete observation time-frame (the total observation period of this study will amount to 90 months).

  13. Patient reported outcomes during treatment with encorafenib plus binimetinib - evaluated with EORTC QLQ C-30

    EORTC QLQ C-30 questionnaires (European Organisation for Research and Treatment of Cancer Quality of Life C-30 questionnaires) to assess quality of life of cancer patients; comprises 30 items, 24 of which are aggregated into nine multi-item scales, that is, five functioning scales (physical, role, cognitive, emotional and social), three symptom scales (fatigue, pain and nausea/vomiting) and one global health status scale. The remaining six single-item (dyspnoea, appetite loss, sleep disturbance, constipation, diarrhoea and the financial impact) scales assess symptoms.

    Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)

  14. Patient reported outcomes during treatment with encorafenib plus binimetinib evaluated with WPAI

    WPAI questionnaires (Work Productivity and Activity Impairment questionnaires). The following questions ask about the effect of patients melanoma on the ability to work and perform regular activities. 1. Are you currently employed (working for pay)? 2. During the past seven days, how many hours did you miss from work because of problems associated with your melanoma? 3. During the past seven days, how many hours did you miss from work because of any other reason? 4. During the past seven days, how many hours did you actually work? 5. During the past seven days, how much did your melanoma affect your productivity while you were working? 6. During the past seven days, how much did your melanoma affect your ability to do your regular daily activities, other than work at a job?

    Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)

  15. Patient reported outcomes during treatment with encorafenib plus binimetinib evaluated with CTSQ

    CTSQ questionnaires (Cancer Therapy Satisfaction Questionnaire) to assess patients' opinions and feelings concerning their cancer therapy and associated adverse events: 1. Questions to patients thoughts about cancer therapy (IV/pills). Scale: \[Always, Most of the time, Some-times, Rarely, Never\]; 2. Questions to patients satisfaction with the most recent cancer therapy (IV/pills): 1. Scale reg. benefit: \[Much better than my expectations Somewhat better than my expectations, Met my expectations, Somewhat worse than my expectations, Much worse than my expectations\]; 2. Scale reg. side effects: \[Much better than I expected, Somewhat better than I expected, Exactly as I expected, Somewhat worse than I expected, Much worse than I expected\]; 3. Scale reg. satisfaction: \[Very satisfied, Satisfied, Neither satisfied nor dissatisfied, Dissatisfied, Very dissatisfied\]; 4. Scale reg. choice of therapy: \[Yes, definitely, Probably Yes, I don't know, Probably not, Definitely not\]

    Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)

  16. Physicians' satisfaction with regard the treatment with encorafenib plus binimetinib

    Physicians' satisfaction questionnaires (measuring Physician's Satisfaction with regard to Effictiveness and Safety, as well as Physician's Overall Treatment Satisfaction) using the following scale construct: 1. Physician's Satisfaction with regard to Efficiency 2. Physician's Satisfaction with regard to Safety 3. Physician's Overall Treatment Satisfaction Scale: * very dissatisfied * dissatisfied * moderately satisfied * satisfied * very satisfied

    Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)

  17. Safety and tolerability of treatment with encorafenib plus binimetinib - Adverse events and adverse reactions including time to onset and time to resolution

    Number of patients with Adverse Events and maximum grade per patient, Adverse Drug Reactions, Adverse Drug Reactions grade 3/4, Serious Adverse Events, Serious Adverse Drug Reactions.

    Time frame: Complete observation time-frame (the total observation period of this study will amount to 90 months).

  18. Prognostic factors

    Influence of prognostic factors on quality of life outcome parameters

    Time frame: Complete observation time-frame (the total observation period of this study will amount to 90 months).

  19. Prognostic factors

    Influence of prognostic factors on effectiveness

    Time frame: Complete observation time-frame (the total observation period of this study will amount to 90 months).

  20. Prognostic factors

    Influence of prognostic factors on safety

    Time frame: Complete observation time-frame (the total observation period of this study will amount to 90 months).

  21. Treatment duration

    From date of first treatment (encorafenib or binimetinib, whichever occurs first) until date of last treatment (encorafenib or binimetinib, whichever occurs last)

    Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)

  22. Treatment dose intensity

    From date of first treatment (encorafenib or binimetinib, whichever occurs first) until date of last treatment (encorafenib or binimetinib, whichever occurs last)

    Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)

  23. Number of treatment interruptions

    From date of first treatment (encorafenib or binimetinib, whichever occurs first) until date of last treatment (encorafenib or binimetinib, whichever occurs last)

    Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)

  24. Duration of treatment interruptions

    From date of first treatment (encorafenib or binimetinib, whichever occurs first) until date of last treatment (encorafenib or binimetinib, whichever occurs last)

    Time frame: From start to end of treatment (anticipated median treatment duration ca. 12 months)

07

Study locations

59 of 59 sites recruiting
  • 11
    Graz, Austria
    Recruiting
  • 13
    Innsbruck, Austria
    Recruiting
  • 14
    Klagenfurt, Austria
    Recruiting
  • 10
    Linz, Austria
    Recruiting
  • 3
    Linz, Austria
    Recruiting
  • 12
    Salzburg, Austria
    Recruiting
  • 23
    Wiener Neustadt, Austria
    Recruiting
  • 22
    Wien, Austria
    Recruiting
  • 53
    Wien, Austria
    Recruiting
  • 45
    Ahaus, Germany
    Recruiting
  • 8
    Aschaffenburg, Germany
    Recruiting
  • 56
    Augsburg, Germany
    Recruiting
  • 51
    Berlin, Germany
    Recruiting
  • 27
    Bremerhaven, Germany
    Recruiting
  • 1
    Buxtehude, Germany
    Recruiting
  • 43
    Chemnitz, Germany
    Recruiting
  • 34
    Donauwörth, Germany
    Recruiting
  • 49
    Dresden, Germany
    Recruiting
  • 47
    Duisburg, Germany
    Recruiting
  • 40
    Erfurt, Germany
    Recruiting
  • 20
    Essen, Germany
    Recruiting
  • 9
    Gera, Germany
    Recruiting
  • 28
    Gießen, Germany
    Recruiting
  • 42
    Goslar, Germany
    Recruiting
  • 59
    Göttingen, Germany
    Recruiting
  • 19
    Hamburg, Germany
    Recruiting
  • 21
    Hannover, Germany
    Recruiting
  • 2
    Heidelberg, Germany
    Recruiting
  • 33
    Karlsruhe, Germany
    Recruiting
  • 39
    Kiel, Germany
    Recruiting
  • 29
    Landshut, Germany
    Recruiting
  • 44
    Leipzig, Germany
    Recruiting
  • 30
    Ludwigshafen, Germany
    Recruiting
  • 4
    Lübeck, Germany
    Recruiting
  • 46
    Magdeburg, Germany
    Recruiting
  • 15
    Mainz, Germany
    Recruiting
  • 5
    Mannheim, Germany
    Recruiting
  • 57
    Marburg, Germany
    Recruiting
  • 6
    Minden, Germany
    Recruiting
  • 31
    München, Germany
    Recruiting
  • 7
    München, Germany
    Recruiting
  • 16
    Münster, Germany
    Recruiting
  • 35
    Münster, Germany
    Recruiting
  • 18
    Nürnberg, Germany
    Recruiting
  • 50
    Regensburg, Germany
    Recruiting
  • 41
    Schorndorf, Germany
    Recruiting
  • 17
    Schwerin, Germany
    Recruiting
  • 48
    Stolberg, Germany
    Recruiting
  • 55
    Trier, Germany
    Recruiting
  • 54
    Tübingen, Germany
    Recruiting
  • 32
    Zwickau, Germany
    Recruiting
  • 52
    Bellinzona, Tessin 6500, Switzerland
    Recruiting
  • 38
    Aarau, Switzerland
    Recruiting
  • 37
    Bern, 3010, Switzerland
    Recruiting
  • 24
    Chur, Switzerland
    Recruiting
  • 36
    Lausanne, Switzerland
    Recruiting
  • 58
    Luzern, 6000, Switzerland
    Recruiting
  • 26
    Winterthur, Switzerland
    Recruiting
  • 25
    Zürich, Switzerland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2019 (actual). Primary completion is estimated for Dec 2026, 86 months after the start.

Of 59 industry-sponsored observational studies under Melanoma, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 80. This study's planned 86 months is above that.

Counting every sponsor, half of 236 studies reached it within 71 months; a quarter within 35 and three quarters within 248.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2019
First posted
Aug 5, 2019
StartActual
Oct 17, 2019
Primary completionEst.
Dec 2026
CompletionEst.
Sep 2027
Last update
Jan 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04045691
Collaborators
Pierre Fabre Pharma Austria, Pierre Fabre Pharma AG
Responsible party
Sponsor
First posted
Aug 5, 2019
Start date
Oct 17, 2019
Primary completion
Dec 2026 (estimated)
Completion
Sep 2027 (estimated)
Last update
Jan 19, 2021

Study contacts

Christian A Rosé, MD
Contact
bering_de@pierre-fabre.com
+49 761 45261 ext. 0
Andrea Schmidt, MSc
Contact
ansc@alcedis.de
+49 641 94436 ext. 0

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion